Watch the Dr. Phil interview with Dr. Poordad
Read More
BARCELONA — Combination therapy with ABT-493, a novel NS3/4A protease inhibitor, and ABT-530, a...
BARCELONA — An investigational drug combination offers renewed hope of a cure for chronic...
BARCELONA — A new three-pronged approach to hepatitis C virus effectively treated prior non-responders...
BARCELONA — In this video perspective from the International Liver Congress, Fred Poordad, MD,...
– 95 percent of patients achieved SVR12 with 12 weeks of ABT-493 and ABT-530...
AbbVie (NYSE: ABBV) announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis...
http://medpagetoday.s3.amazonaws.com/media/sponsors/hothcv/Pipeline2.mp4 MedPage Today invited specialists from leading medical institutions to weigh in on the...
The U.S. Food and Drug Administration has granted amended Breakthrough Therapy Designation for an...
MedPage Today invited specialists from leading medical institutions to weigh in on the latest...